Check out our new review article in The Lancet Haematology ⤵️ “Immune effector cell-associated hematotoxicity after CAR T-cell therapy: from mechanism to management” ➡️ We summarize all that we currently know and understand about CAR-T related cytopenias. thelancet.com/journals/lanha…

Finally out in Nature Reviews Cancer! Our "guide to artificial intelligence for cancer researchers", with Raquel Perez-Lopez Narmin Ghaffari Laleh Faisal Mahmood 🤩 article: nature.com/articles/s4156… full text: rdcu.be/dH7Z6 Hochschulmedizin_TUD Universitätsklinikum Heidelberg Nationales Centrum für Tumorerkrankungen Dresden NCT Heidelberg

Excited to share our new study of risk of T-cell #lymphomas after #CAR therapy. 1/15 🧵 nejm.org/doi/full/10.10…

Proud of this comprehensive review published in ⁦Nature Reviews Disease Primers⁩ - This was a wonderful team effort during several months. Thank you ⁦Florent Malard⁩ ⁦, nizar jacques bahlis, P. Neri, E Terpos, N. Moukalled, VTM. Hungria, and S. Manier ⁦IACH⁩ ⁦COMy⁩

Here is the summary of ⁦IACH⁩ activities during the first 6 months of 2024. THANK YOU all for you support to our «Hematology without Borders» vision. clinical-hematology.org

🚨 hot off the press 🚨 A (perhaps) underestimated aspect of CAR T-cell therapy: non-relapse mortality. Check out our new meta-analysis on this clinically relevant topic - out today in Nature Medicine ! nature.com/articles/s4159… Let’s take a deeper dive! Start 🧵

Just out Nature Medicine meta-analysis >7600 CAR T pts led by David Cordas dos Santos & Kai Rejeski - Non-relapse mortality post CAR-T = 6.8% - highest w ciltacel (15%) & brexucel (10.6%) - axicel (7%) > tisa-/lisocel (4%) for LBCL - 51% of NRM deaths from infection nature.com/articles/s4159…

Fresh off the press, exciting results from Frank et al Stanford Medicine CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study thelancet.com/journals/lance… Looking forward to the multicenter phase 2

CD19-directed CART Therapy for T cell/Histiocyte Rich Large B-cell Lymphoma #lymsm Priyanka Pophali, MD Joshua Fein Mazyar Shadman, MD MPH Roni Shouval Nausheen Ahmed MD et al. N=58 2-year OS 42%, PFS 29% (better than initial reports) ashpublications.org/bloodadvances/…

It was a pleasure discussing some of the clinical implications of our recent Nature Medicine publication on CAR-T related NRM in a Q&A with Memorial Sloan Kettering Cancer Center 👇 #nrm #infections #spm #cartsm #lymsm #mmsm Roni Shouval Miguel Perales M.D. mskcc.org/clinical-updat…

Excited to share our latest work out today in Journal of Clinical Oncology A collaborative work with many colleagues Steven Devine Mahasweta Gooptu Antonio Jimenez Jimenez Monzr M. AlMalki, MD Jeff Auletta Martin Maiers and many others. ascopubs.org/doi/10.1200/JC…

Congrats to the now Dr. Ruchi Patel for the publication of her PhD thesis in Science Immunology. We show here that CD5 deletion enhances CART immunotherapy in multiple solid and liquid cancer models. Penn Medicine Ruella Lab science.org/doi/10.1126/sc…

Summer BBQ in NYC Scherz Shouval Lab next generation. What a great afternoon Memorial Sloan Kettering Cancer Center

📣 Major milestone reached: 10,000 CAR-T treated #patients registered in the #EBMT Registry! 🙌 📈 This achievement highlights the incredible progress and growing impact of chimeric antigen receptor T-cell (CAR-T) therapy in treating haematological malignancies. 🔬 We are very

📢 Hot off the press! CAFs are major regulators of the immune tumor microenvironment. In our new review we dissect a fascinating aspect of this regulation: CAF-induced physical constraints controlling T cell state and localization in solid tumours nature.com/articles/s4156…

🚨🚨I’m excited to present our lab’s new paper where we tried to provide a mechanistic explanation for the link between antibiotic use and risk of developing inflammatory bowel diseases (#IBD). A 🧵/1 science.org/doi/10.1126/sc…

Excited to share our new paper focusing on Second Primary Malignancies (SPMs) following CAR T-cell therapy out today in Clinical Cancer Research ! 👇 This first-in-kind meta-analysis spans 5,517 lymphoma and myeloma patients receiving a range of CAR-T products. aacrjournals.org/clincancerres/…

Stuck in Friday rush-hour traffic? Perfect time to listen to our conversation with Adam Kittai about CART and BMT in treating CLL and Richter's Transformation Apple podcasts: podcasts.apple.com/us/podcast/sea… Spotify: open.spotify.com/episode/3AoyV6… shows.acast.com/chimerically-s…